SGMT
Sagimet Biosciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.94
+0.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | 2.0M | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | 2.0M | — |
| Operating Expenses | |||||
| R&D Expense | 35.0M | 39.1M | 38.4M | 19.8M | 24.9M |
| SG&A Expense | 17.6M | 17.8M | 16.0M | 13.0M | 6.1M |
| General & Admin Expense | 17.6M | 17.8M | 16.0M | 13.0M | 6.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 52.6M | 56.9M | 54.5M | 32.7M | 31.1M |
| Cost and Expenses | 52.6M | 56.9M | 54.5M | 32.7M | 31.1M |
| Operating Income (EBIT) | (52.6M) | (56.9M) | (54.5M) | (30.7M) | (31.1M) |
| Non-Operating | |||||
| Interest Income | (739.0K) | 5.9M | 8.9M | 2.9M | 553.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | (739.0K) | 5.9M | 8.9M | 2.9M | 553.0K |
| Other Non-Op Income/Expense | 5.6M | 5.9M | 8.9M | 2.9M | 556.0K |
| Non-Operating Income (excl Interest) | (2.9M) | (5.9M) | (8.9M) | (2.9M) | (556.0K) |
| EBT (Pre-Tax Income) | (47.1M) | (51.0M) | (45.6M) | (27.9M) | (30.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (47.1M) | (51.0M) | (45.6M) | (27.9M) | (30.5M) |
| Earnings from Cont. Ops | (47.1M) | (51.0M) | (45.6M) | (27.9M) | (30.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (47.1M) | (51.0M) | (45.6M) | (27.9M) | (30.5M) |
| Per Share | |||||
| Basic EPS | ($1.28) | ($1.58) | ($1.45) | ($1.53) | ($1.38) |
| Diluted EPS | ($1.28) | ($1.58) | ($1.45) | ($1.53) | ($1.38) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.11 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 53.1M | 32.3M | 31.4M | 18.2M | 22.2M |
| Diluted Shares Outstanding | 53.1M | 32.3M | 31.4M | 18.2M | 22.2M |
| Profitability Metrics | |||||
| EBITDA | (49.7M) | (51.0M) | (45.6M) | (27.9M) | (30.4M) |
| D&A | — | — | — | — | 130.0K |
| EBIT | (49.7M) | (51.0M) | (45.6M) | (27.9M) | (30.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026